The estimated Net Worth of Michael Brian Bell is at least $7.77 Milione dollars as of 15 June 2024. Mr. Bell owns over 9,267 units of Caredx Inc stock worth over $619,672 and over the last 8 years he sold CDNA stock worth over $4,794,142. In addition, he makes $2,358,100 as Chief Financial Officer at Caredx Inc.
Michael has made over 19 trades of the Caredx Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 9,267 units of CDNA stock worth $264,388 on 15 June 2024.
The largest trade he's ever made was selling 57,136 units of Caredx Inc stock on 6 May 2020 worth over $1,656,944. On average, Michael trades about 5,504 units every 62 days since 2017. As of 15 June 2024 he still owns at least 21,720 units of Caredx Inc stock.
You can see the complete history of Mr. Bell stock trades at the bottom of the page.
Michael Bell is Chief Financial Officer of the Company, effective April 21, 2017. He has over 20 years of international finance and accounting experience. From January 2016 to March 2017, Mr. Bell served as the Chief Financial Officer of Metabiota, Inc., a San Francisco-based company that develops and sells risk analytics products focused on infectious disease. From May 2012 to January 2016, he served as the Chief Financial Officer of Singulex, Inc., a clinical diagnostics company. Prior to that, Mr. Bell held leadership and executive positions within Novartis, including with Novartis Diagnostics, a global provider of blood screening solutions, where he served as Chief Financial Officer from 2011 to 2012, and Senior Director, Global Head of Finance from 2008 to 2011. Mr. Bell also previously worked for several years in public accounting with both Ernst & Young LLP and Deloitte, UK. He holds a Bachelor of Science degree in Mathematics with Computing from the University of Leicester in the United Kingdom, and is a Fellow of the Institute of Chartered Accountants in England & Wales.
As the Chief Financial Officer of Caredx Inc, the total compensation of Michael Bell at Caredx Inc is $2,358,100. There are 1 executives at Caredx Inc getting paid more, with Peter Maag having the highest compensation of $8,855,740.
Michael Bell is 51, he's been the Chief Financial Officer of Caredx Inc since 2017. There are 8 older and 8 younger executives at Caredx Inc. The oldest executive at Caredx Inc is Ralph Snyderman, 80, who is the Independent Director.
Michael's mailing address filed with the SEC is 3100, Hanover Street, Palo Alto, Santa Clara County, California, 94306, United States.
Over the last 10 years, insiders at Caredx Inc have traded over $60,271,359 worth of Caredx Inc stock and bought 1,726,634 units worth $9,072,700 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Neil Gagnon e Peter Maag. On average, Caredx Inc executives and independent directors trade stock every 17 days with the average trade being worth of $615,506. The most recent stock trade was executed by Alexander L Johnson on 20 August 2024, trading 61,023 units of CDNA stock currently worth $1,432,820.
caredx: transforming transplant patient care through novel surveillance management solutions caredx, inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. by combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, caredx is at the forefront of organ transplant surveillance and pre-transplant hla typing solutions. nasdaq:cdna about allosure® allosure is the first and only non-invasive blood test that directly measures allograft injury and identifies the probability of active rejection to better manage kidney transplant patients. allosure is a clinical-grade, proprietary next-generation sequencing (ngs) based test to detect donor-derived cell-free dna (dd-cfdna) in order to identify organ injury in kidney transplant recipients. allosure is analytically validated as a sensitive, specific, and precise measurement of dd-cfdna. allos
Caredx Inc executives and other stock owners filed with the SEC include: